Cancer Drugs

AbbVie lowers first-quarter steerage after closing acquisition ImmunoGen

J&J, Merck and Bristol Myers CEOs, below fireplace on Capitol Hill, search to show up warmth on drug-market middlemen 

Novartis to bolster its oncology portfolio with acquisition of MorphoSys

Cancer-treatment developer CG Oncology information for IPO

Iovance inventory drops 24% after it halts cancer-drug trial

Sanofi suffers main blow as its cutting-edge most cancers drug disappoints in Phase III trials

Wuxi XDC Cayman shares surge in Hong Kong debut

WuXi XDC units its Hong Kong IPO value at excessive finish of vary

AstraZeneca hikes earnings forecast as surging most cancers drug gross sales offset plunging income from COVID vaccines

Daiichi Sankyo shares bounce on multibillion-dollar drug improvement cope with Merck